These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 11001685)

  • 1. Ropinirole as compared with levodopa in Parkinson's disease.
    Yamamoto T
    N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001685
    [No Abstract]   [Full Text] [Related]  

  • 2. Ropinirole as compared with levodopa in Parkinson's disease.
    Weiner WJ; Factor SA
    N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001687
    [No Abstract]   [Full Text] [Related]  

  • 3. Ropinirole as compared with levodopa in Parkinson's disease.
    Frucht S
    N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001686
    [No Abstract]   [Full Text] [Related]  

  • 4. Ropinirole as compared with levodopa in Parkinson's disease.
    Hiner BC; Earnhart M
    N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684
    [No Abstract]   [Full Text] [Related]  

  • 5. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
    Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
    Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE; Abdalla M;
    Mov Disord; 2006 Nov; 21(11):1844-50. PubMed ID: 16958094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE
    N Engl J Med; 2000 May; 342(20):1484-91. PubMed ID: 10816186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 10. Rating scales for dyskinesias in Parkinson's disease.
    Goetz CG
    Mov Disord; 1999; 14 Suppl 1():48-53. PubMed ID: 10493403
    [No Abstract]   [Full Text] [Related]  

  • 11. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 12. Serpentine tongue: A rare manifestation following initiation of levodopa therapy in a patient with Parkinson's disease.
    Prashantha DK; Pal PK
    Parkinsonism Relat Disord; 2009 Nov; 15(9):718-9. PubMed ID: 19157953
    [No Abstract]   [Full Text] [Related]  

  • 13. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y
    Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399
    [No Abstract]   [Full Text] [Related]  

  • 14. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Rascol O
    Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400
    [No Abstract]   [Full Text] [Related]  

  • 16. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
    Tousi B; Subramanian T
    Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
    [No Abstract]   [Full Text] [Related]  

  • 19. Medical treatment of Parkinson's disease.
    Ahlskog JE
    Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
    [No Abstract]   [Full Text] [Related]  

  • 20. [Long-term complications of treatment with levodopa].
    Castro García A; Sesar Ignacio A
    Neurologia; 1998; 13 Suppl 1():41-8. PubMed ID: 9859685
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.